Fidelity International
RARX

Fidelity International’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Fidelity International’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-104,400
Closed -$1.96M – 532
2017
Q2 		$1.96M Hold
104,400
– – 0.01% 456
2017
Q1 		$2.22M Sell
104,400
-25,600
-20% -$489K 0.01% 464
2016
Q4 		$1.98M Buy
+130,000
New +$1.77M 0.01% 464

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International's RARX Position: Q3 2017 in Review

Fidelity International sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2017, closing a stake of 104,400 shares — an estimated $1.96M sold.

Fidelity International first reported a position in RARX in Q4 2016 and held it in 3 quarters. The position peaked at $2.22M in Q1 2017. 64 funds tracked by Wall St. Rank hold RARX as of Q3 2017.

  • Fidelity International reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Fidelity International sold 104,400 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2017, an estimated $1.96M.
  • Fidelity International first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 3 quarters.
  • Fidelity International's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.22M in Q1 2017.
  • 64 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2017.

Based on Fidelity International's 13F filing for Q3 2017, filed 13 Nov 2017.